本文へ移動
AI NEWS JOURNAL
arXiv cs.LGAI NEWS / JOURNAL

ReMedI:制御可能な分子最適化のための推論時精緻化と自己蒸留

arXiv:2610.32103v1 発表タイプ:新規 要旨:創薬において、リード最適化では、透過性の向上や毒性の低減といった相反する特性を改善しつつ、リードの活性を損なう可能性のあるスケルトン変更を抑制しなければなりません。C-MORAL などの強化学習ベースのポストトレーニング手法は、分子言語モデルを微調整することで、関心のある目的に対して直接的に分子リードを最適化するというアプローチを採用していますが、これには高価なタスク固有のデータセットが必要であり、多目的最適化(MOO)の実現にも課題が伴います。我々は、事前学習済みモデルには、ゼロショット生成では効率的に到達できない有用な分子改変がすでに含まれている可能性があると主張します。ゼロショット生成の探索能力の限界に着目し、我々は効率的なメトロポリス・ハスティングス探索戦略を開発し、bet

翻訳待ちです。完了すると自動更新されます。

Abstract:In drug development, lead optimization must improve competing properties, such as increasing permeability and reducing toxicity, while limiting scaffold changes that could compromise the lead's potency. RL-based post-training, such as C-MORAL, addresses this problem by fine-tuning molecular language models to directly optimize molecular leads for objectives of interest, which relies on expensive task-specific datasets and faces challenges in achieving multi-objective optimization (MOO). We argue a pre-trained model may already contain useful molecular edits that zero-shot generation cannot efficiently reach. Motivated by the limited search capabilities of zero-shot generation, we develop an efficient Metropolis-Hastings search strategy to better explore the proposal distribution. We propose ReMedI, which uses the molecular language model as a base proposer for inference-time alignment. Given a lead and a set of multi-objective tasks, the model proposes edits conditioned on the current molecule, while Metropolis--Hastings refinement guides sequential edits under an objective for property improvement, preservation, and lead similarity. On both C-MuMOInstruct and SMDD benchmarks, refinement improves frozen base models across three backbones, reaching significantly higher multi-objective optimization success rates compared to baselines. These search traces can then distilled into the base model which improves zero-shot generation and subsequent search using approximately 7.8 times less training molecular leads than that of C-MORAL. ReMedI achieves approximately 2.8 times the strict-success coverage of RL baseline C-MORAL, including on out-of-distribution tasks, with matched lead-relative similarity.

Submission history

Access Paper:

View PDF

HTML (experimental)

TeX Source

Additional Features

Audio Summary

Current browse context:

References & Citations

Google Scholar

Semantic Scholar

Bookmark

Institution

arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.

Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.

Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.

情報源

arXiv cs.LG
← すべてのニュースへ